BRIEF-Metacrine Reports Interim Results For Met642 Phase 2A Trial In Patients With NASH
BRIEF-Metacrine Reports Interim Results For Met642 Phase 2A Trial In Patients With NASH
Oct 21 (Reuters) - Metacrine, Inc. MTCR.O :
路透10月21日電-Metacine，Inc.。MTCR.O：
* METACRINE REPORTS INTERIM RESULTS FOR MET642 PHASE 2A TRIAL IN PATIENTS WITH NASH AND ANNOUNCES A STRATEGIC RE-PRIORITIZATION OF ITS CLINICAL DEVELOPMENT PROGRAMS
*METACRINE報告了MET642期2A期NASH患者試驗的中期結果，並宣佈對其臨牀開發計劃進行戰略重新排序
* METACRINE - PRIORITIZING CLINICAL DEVELOPMENT EFFORT AND RESOURCES TO ADVANCE MET642 INTO A PHASE 2 TRIAL IN IBD IN FIRST HALF OF 2022
*METACRINE-優先考慮臨牀開發工作和資源，以在2022年上半年將MET642推進為IBD的2期試驗
* METACRINE, INC. - EXPECTS INDEPENDENT REVIEW OF MET642 TO BE COMPLETED BEFORE END OF 2021
*METACRINE，Inc.-預計在2021年底之前完成對MET642的獨立審查
* METACRINE, INC. - CONDUCTING AN INDEPENDENT REVIEW OF PRELIMINARY FINDINGS FROM A RECENTLY COMPLETED NINE-MONTH ANIMAL TOXICOLOGY STUDY FOR MET642
*METACRINE，Inc.-對最近完成的為期9個月的MET642動物毒理學研究的初步結果進行獨立審查
* METACRINE, INC. - TO HALT FUTURE DEVELOPMENT OF FXR PROGRAM IN NASH
*METACRINE，Inc.-停止未來在納什開發FXR計劃
* METACRINE, INC. - DECISION WAS INFLUENCED IN PART BY A POTENTIAL DELAY IN CONFIRMING APPROPRIATE SAFETY MARGINS IN LONG-TERM TOXICOLOGY WORK
*METACRINE，Inc.-決定在一定程度上受到長期毒理學工作中在確定適當安全邊際方面的潛在延誤的影響
* METACRINE, INC. - MET642 WAS GENERALLY WELL-TOLERATED, WITH NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS
*METACRINE，Inc.--MET642總體耐受性良好，未出現與治療相關的嚴重不良反應
Source text for Eikon: Further company coverage:
Eikon的源文本：進一步的公司報道：
譯文內容由第三人軟體翻譯。